Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Driven by SpaceX's transformative IPO and AI hosting deals, semiconductor strength from NVIDIA and TSMC, and accelerating AI adoption across CrowdStrike, Datadog, and Snowflake. The manager views SpaceX as the ultimate N=1 opportunity at the intersection of AI and space economy.
Full Quick Take
Driven by SpaceX's transformative IPO and AI hosting deals, semiconductor strength from NVIDIA and TSMC, and accelerating AI adoption across CrowdStrike, Datadog, and Snowflake. The manager views SpaceX as the ultimate N=1 opportunity at the intersection of AI and space economy.
ClearBridge All Cap Growth underperformed in Q2 as mega cap AI leadership resumed following tariff volatility, with the Strategy's diversified positioning creating a headwind versus the concentrated benchmark.
Full Quick Take
ClearBridge All Cap Growth underperformed in Q2 as mega cap AI leadership resumed following tariff volatility, with the Strategy's diversified positioning creating a headwind versus the concentrated benchmark.
Oak Ridge capitalized on AI-driven market strength with concentrated exposure to semiconductors, memory, and data centers delivering exceptional returns. The manager trimmed positions after extraordinary runs but maintains overweight exposure to AI beneficiaries.
Full Quick Take
Oak Ridge capitalized on AI-driven market strength with concentrated exposure to semiconductors, memory, and data centers delivering exceptional returns. The manager trimmed positions after extraordinary runs but maintains overweight exposure to AI beneficiaries.
The fund holds concentrated positions in infrastructure beneficiaries like CRH, fintech monetization plays like Block, and AI datacenter power through Flex, complemented by an alpha-generating short book.
Full Quick Take
The fund holds concentrated positions in infrastructure beneficiaries like CRH, fintech monetization plays like Block, and AI datacenter power through Flex, complemented by an alpha-generating short book.
Driven by AI semiconductor infrastructure (SK hynix, Samsung) and healthcare innovation (Lantheus M&A, CVS GLP-1). The manager rotated from richly valued names into Adobe, Fujifilm, UniCredit, and Booking Holdings, viewing market concentration as creating value dislocations.
Full Quick Take
Driven by AI semiconductor infrastructure (SK hynix, Samsung) and healthcare innovation (Lantheus M&A, CVS GLP-1). The manager rotated from richly valued names into Adobe, Fujifilm, UniCredit, and Booking Holdings, viewing market concentration as creating value dislocations.
Abrdn's international small-cap fund outperformed in Q2 2026 on AI infrastructure strength. The manager trimmed AI winners and rotated into semiconductor equipment, GLP-1 manufacturing, and emerging market telecom infrastructure.
Full Quick Take
Abrdn's international small-cap fund outperformed in Q2 2026 on AI infrastructure strength. The manager trimmed AI winners and rotated into semiconductor equipment, GLP-1 manufacturing, and emerging market telecom infrastructure.
Outperforming on strong semiconductor and biotech stock selection. The portfolio participated in AI infrastructure appreciation while maintaining discipline, with multiple semiconductor positions up over 100%.
Full Quick Take
Outperforming on strong semiconductor and biotech stock selection. The portfolio participated in AI infrastructure appreciation while maintaining discipline, with multiple semiconductor positions up over 100%.
Driven by AI-related semiconductor holdings Murata and Kokusai Electric reaching record highs as demand broadened beyond chipmakers. The manager added Tokyo Electron on semiconductor infrastructure strength while exiting Mitsui Fudosan on capital allocation concerns.
Full Quick Take
Driven by AI-related semiconductor holdings Murata and Kokusai Electric reaching record highs as demand broadened beyond chipmakers. The manager added Tokyo Electron on semiconductor infrastructure strength while exiting Mitsui Fudosan on capital allocation concerns.
Portfolio pivoted from technology to biotechnology with Eli Lilly as largest position on GLP-1 growth, while maintaining AI exposure across infrastructure and chips. Inflation at 4.2% driving Fed toward rate hikes.
Full Quick Take
Portfolio pivoted from technology to biotechnology with Eli Lilly as largest position on GLP-1 growth, while maintaining AI exposure across infrastructure and chips. Inflation at 4.2% driving Fed toward rate hikes.
Oak Ridge navigated Q1 2026 geopolitical turmoil by positioning around AI infrastructure opportunities while managing energy-driven inflation risks. Strong performance from data center power providers offset broader tech corrections.
Full Quick Take
Oak Ridge navigated Q1 2026 geopolitical turmoil by positioning around AI infrastructure opportunities while managing energy-driven inflation risks. Strong performance from data center power providers offset broader tech corrections.
Strong Q3 performance driven by AI leaders like AppLovin and biotechnology recovery play Medpace. Healthcare holdings faced headwinds from rising costs and GLP-1 competition.
Full Quick Take
Strong Q3 performance driven by AI leaders like AppLovin and biotechnology recovery play Medpace. Healthcare holdings faced headwinds from rising costs and GLP-1 competition.
Driven by strong biotechnology stock selection, particularly argenx and Insmed benefiting from drug approvals. AI-enabled healthcare solutions like RadNet and Heartflow also contributed.
Full Quick Take
Driven by strong biotechnology stock selection, particularly argenx and Insmed benefiting from drug approvals. AI-enabled healthcare solutions like RadNet and Heartflow also contributed.
Oak Ridge's growth strategy focuses on AI transformation while managing concentration risk in mega-cap dominated markets. Healthcare holdings detracted in Q2 despite strong overall market performance.
Full Quick Take
Oak Ridge's growth strategy focuses on AI transformation while managing concentration risk in mega-cap dominated markets. Healthcare holdings detracted in Q2 despite strong overall market performance.
ClearBridge All Cap Growth underperformed in Q2 2025's risk-on rebound due to diversified positioning versus concentrated benchmark. Health care holdings weighed on performance while AI and streaming names contributed.
Full Quick Take
ClearBridge All Cap Growth underperformed in Q2 2025's risk-on rebound due to diversified positioning versus concentrated benchmark. Health care holdings weighed on performance while AI and streaming names contributed.
Oak Ridge's growth strategies delivered solid Q2 performance despite tariff volatility, driven by AI leadership in technology and selective healthcare positioning. The firm trimmed winners to manage concentration while maintaining conviction in transformative trends.
Full Quick Take
Oak Ridge's growth strategies delivered solid Q2 performance despite tariff volatility, driven by AI leadership in technology and selective healthcare positioning. The firm trimmed winners to manage concentration while maintaining conviction in transformative trends.
Ithaka delivered 540bps of outperformance in Q2 2025 despite tariff volatility, driven by AI leaders Nvidia and Microsoft. The concentrated growth portfolio weathered Trump's trade policy uncertainty while capitalizing on strong fundamentals and Fed pause expectations.
Full Quick Take
Ithaka delivered 540bps of outperformance in Q2 2025 despite tariff volatility, driven by AI leaders Nvidia and Microsoft. The concentrated growth portfolio weathered Trump's trade policy uncertainty while capitalizing on strong fundamentals and Fed pause expectations.
Particularly Alibaba's 60% gain from narrative shift. Added Hershey and Nike during temporary headwinds from cocoa prices, GLP-1 drugs, and tariff uncertainty.
Full Quick Take
Particularly Alibaba's 60% gain from narrative shift. Added Hershey and Nike during temporary headwinds from cocoa prices, GLP-1 drugs, and tariff uncertainty.
International equities broke their 13-year underperformance streak in Q1 2025, led by Europe's fiscal stimulus and China's regulatory improvements. The manager opportunistically bought Novo Nordisk after its 50% decline, capitalizing on the GLP-1 obesity opportunity.
Full Quick Take
International equities broke their 13-year underperformance streak in Q1 2025, led by Europe's fiscal stimulus and China's regulatory improvements. The manager opportunistically bought Novo Nordisk after its 50% decline, capitalizing on the GLP-1 obesity opportunity.
Global Alpha used Q1 volatility to upgrade positions, adding Nubank, Enphase Energy, and Salesforce while disruptive names faced pressure. The team sees broad growth opportunities across AI value chain, US infrastructure spending, and GLP-1 drugs.
Full Quick Take
Global Alpha used Q1 volatility to upgrade positions, adding Nubank, Enphase Energy, and Salesforce while disruptive names faced pressure. The team sees broad growth opportunities across AI value chain, US infrastructure spending, and GLP-1 drugs.
Brown Capital's International All Company Fund underperformed in Q1 2025 as growth stocks lagged value, but the manager remains confident in their Exceptional Growth Company strategy.
Full Quick Take
Brown Capital's International All Company Fund underperformed in Q1 2025 as growth stocks lagged value, but the manager remains confident in their Exceptional Growth Company strategy.
Outperforming its benchmark despite Magnificent 7 tech stock pullbacks from valuation concerns and Trump tariff announcements. Uber, Visa, and Eli Lilly were top contributors while NVIDIA, Alphabet, and Apple detracted.
Full Quick Take
Outperforming its benchmark despite Magnificent 7 tech stock pullbacks from valuation concerns and Trump tariff announcements. Uber, Visa, and Eli Lilly were top contributors while NVIDIA, Alphabet, and Apple detracted.
Baron Health Care Fund matched benchmark returns in Q3 2025, driven by strong biotechnology stock selection including argenx and Insmed. AI-enabled healthcare solutions like RadNet and Heartflow also contributed.
Full Quick Take
Baron Health Care Fund matched benchmark returns in Q3 2025, driven by strong biotechnology stock selection including argenx and Insmed. AI-enabled healthcare solutions like RadNet and Heartflow also contributed.
Polen Focus Growth outperformed during Q1 2025's tariff-driven volatility.0%. The firm shifted toward safety-oriented holdings, initiating Starbucks and Aon positions while exiting Novo Nordisk.
Full Quick Take
Polen Focus Growth outperformed during Q1 2025's tariff-driven volatility.0%. The firm shifted toward safety-oriented holdings, initiating Starbucks and Aon positions while exiting Novo Nordisk.
Fundsmith underperformed in 2024 due to extreme market concentration in mega-cap tech stocks, but maintains superior portfolio quality metrics. The fund sold Apple and Diageo while adding Atlas Copco and Texas Instruments.
Full Quick Take
Fundsmith underperformed in 2024 due to extreme market concentration in mega-cap tech stocks, but maintains superior portfolio quality metrics. The fund sold Apple and Diageo while adding Atlas Copco and Texas Instruments.
Polen Focus Growth delivered solid Q4 performance while maintaining discipline amid a frothy market dominated by Magnificent 7 concentration. The fund added quality names like CoStar Group and trimmed overvalued positions.
Full Quick Take
Polen Focus Growth delivered solid Q4 performance while maintaining discipline amid a frothy market dominated by Magnificent 7 concentration. The fund added quality names like CoStar Group and trimmed overvalued positions.
Polen Global Growth outperformed in Q4 despite software sector headwinds from AI narratives. Strong contributors included Shopify, Amazon, and Paycom, while ICON and Novo Nordisk detracted.
Full Quick Take
Polen Global Growth outperformed in Q4 despite software sector headwinds from AI narratives. Strong contributors included Shopify, Amazon, and Paycom, while ICON and Novo Nordisk detracted.
The manager believes market concentration will persist as AI enters the Agentic Age, driving productivity gains. Portfolio changes included repurchasing Charter and Snowflake while exiting Alphabet on regulatory concerns.
Full Quick Take
The manager believes market concentration will persist as AI enters the Agentic Age, driving productivity gains. Portfolio changes included repurchasing Charter and Snowflake while exiting Alphabet on regulatory concerns.
The portfolio remains concentrated in AI, cloud, and e-commerce leaders like Amazon, NVIDIA, and Shopify. Despite some headwinds from rising rates and sector rotation, the manager maintains conviction in secular growth themes.
Full Quick Take
The portfolio remains concentrated in AI, cloud, and e-commerce leaders like Amazon, NVIDIA, and Shopify. Despite some headwinds from rising rates and sector rotation, the manager maintains conviction in secular growth themes.
Hardman Johnston's international equity strategy significantly outperformed benchmarks in Q4 2024 through superior stock selection, particularly in Technology and Financials. TSMC and Atlassian drove tech gains while Standard Chartered led financials.
Full Quick Take
Hardman Johnston's international equity strategy significantly outperformed benchmarks in Q4 2024 through superior stock selection, particularly in Technology and Financials. TSMC and Atlassian drove tech gains while Standard Chartered led financials.
Brown Capital's International Fund outperformed benchmarks despite 6.72% Q4 decline, benefiting from service-heavy portfolio positioning amid tariff concerns.
Full Quick Take
Brown Capital's International Fund outperformed benchmarks despite 6.72% Q4 decline, benefiting from service-heavy portfolio positioning amid tariff concerns.
The fund's secular-themed strategy focuses on structural growth trends while shorting cyclical decliners. Despite rising bond yield pressures, the manager believes their thematic positioning in AI, e-commerce, and cloud computing will drive continued outperformance.
Full Quick Take
The fund's secular-themed strategy focuses on structural growth trends while shorting cyclical decliners. Despite rising bond yield pressures, the manager believes their thematic positioning in AI, e-commerce, and cloud computing will drive continued outperformance.
ClearBridge's diversified large cap growth strategy underperformed momentum-driven markets in Q4 but used dislocations to add healthcare and consumer discretionary exposure through new positions in Novo Nordisk and Airbnb.
Full Quick Take
ClearBridge's diversified large cap growth strategy underperformed momentum-driven markets in Q4 but used dislocations to add healthcare and consumer discretionary exposure through new positions in Novo Nordisk and Airbnb.
International growth strategy outperformed despite tariff concerns and European political turmoil. Strong stock selection in e-commerce and stable growers offset pharmaceutical weakness.
Full Quick Take
International growth strategy outperformed despite tariff concerns and European political turmoil. Strong stock selection in e-commerce and stable growers offset pharmaceutical weakness.
The quality-focused strategy emphasizes durable growth companies with valuation discipline. Strong performance from technology and financial holdings offset weakness in healthcare names.
Full Quick Take
The quality-focused strategy emphasizes durable growth companies with valuation discipline. Strong performance from technology and financial holdings offset weakness in healthcare names.
Outperforming biotech indices. The fund focuses on transformative life sciences assets with 54 core positions spanning genetic medicines, obesity treatments, and rare diseases.
Full Quick Take
Outperforming biotech indices. The fund focuses on transformative life sciences assets with 54 core positions spanning genetic medicines, obesity treatments, and rare diseases.
ClearBridge's value strategy underperformed in Q2 as AI concentration punished perceived losers while rewarding winners. The team sees this valuation divergence creating opportunities in underappreciated quality companies.
Full Quick Take
ClearBridge's value strategy underperformed in Q2 as AI concentration punished perceived losers while rewarding winners. The team sees this valuation divergence creating opportunities in underappreciated quality companies.
International Growth Fund underperformed in Q2 as financials and materials holdings weighed on returns while technology positions helped. The fund added consumer staples positions and reduced cyclical exposure.
Full Quick Take
International Growth Fund underperformed in Q2 as financials and materials holdings weighed on returns while technology positions helped. The fund added consumer staples positions and reduced cyclical exposure.
Oak Ridge navigates unprecedented market concentration in Mega-Cap technology while maintaining exposure to leaders and seeking emerging opportunities. Their largest bet on GLP-1 pharmaceuticals has delivered exceptional returns.
Full Quick Take
Oak Ridge navigates unprecedented market concentration in Mega-Cap technology while maintaining exposure to leaders and seeking emerging opportunities. Their largest bet on GLP-1 pharmaceuticals has delivered exceptional returns.
Diamond Hill's international strategy underperformed in Q2 despite strong AI-related gains from Taiwan Semiconductor and Tencent. The firm added four new positions while maintaining disciplined value approach amid sector disruptions in AI, electric vehicles, and healthcare.
Full Quick Take
Diamond Hill's international strategy underperformed in Q2 despite strong AI-related gains from Taiwan Semiconductor and Tencent. The firm added four new positions while maintaining disciplined value approach amid sector disruptions in AI, electric vehicles, and healthcare.
Viking Therapeutics led gains on GLP-1 results while fertilizer holdings detracted. Fund maintains value investing conviction amid momentum-driven markets favoring mega-caps.
Full Quick Take
Viking Therapeutics led gains on GLP-1 results while fertilizer holdings detracted. Fund maintains value investing conviction amid momentum-driven markets favoring mega-caps.